Printer Friendly

BENJAMIN MATZILEVICH NAMED ENDOGEN, INC. VICE PRESIDENT OF MARKETING AND SALES

 BOSTON, Aug. 23 /PRNewswire/ -- Owen A. Dempsey, president and chief executive officer of Endogen, Inc. (OTC: ENDG) announced today that Benjamin Matzilevich has been named vice president of marketing and sales effective immediately. Matzilevich joins Endogen from BioSource International.
 "Ben brings to Endogen tremendous experience and strategic insight based on over 15 years in the research products and diagnostics industries. His expertise greatly enhances Endogen's ability to serve our customers in the research products market," said Dempsey. "We are delighted that he has joined the Endogen team."
 Matzilevich brings over 15 years of senior management, sales and marketing experience to Endogen. In 1989 he co-founded BioSource International and beginning 1990, served as vice president of marketing and sales. Previously, Matzilevich was the vice president of marketing and sales at both Verax Corporation and BioLogicals, Inc., and consulted for the diagnostics industry. From 1976 to 1981, Matzilevich was the senior product manager of New England Nuclear, where revenues increased from $17 million to $47 million during this period.
 Endogen, Inc. is a leading developer, manufacturer and supplier of specialty research products and immuno-assay test kits to the growing biomedical research market. The company's products are used by researchers who are investigating cytokines, adhesion molecules, and other components of the immune system. Endogen markets three principal products lines worldwide, consisting of over 120 research products and 19 immuno-assay kits.
 -0- 8/23/93
 /CONTACT: Owen A. Dempsey, president and CEO of Endogen, Inc., 617-439-3250/
 (ENDG)


CO: Endogen, Inc. ST: Massachusetts IN: MTC SU: PER

CM -- NE002 -- 4913 08/23/93 08:18 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 23, 1993
Words:261
Previous Article:NEUTROGENA REPORTS THIRD QUARTER RESULTS
Next Article:AILEEN, INC. REPORTS THIRD QUARTER RESULTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters